Sarepta Therapeutics Names Michael Severino As CEO; Shares Rise In Pre-Market

Sarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.

Sarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.

Sarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments – New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, b

Sarepta Therapeutics said Michael Severino will become CEO effective July 28, replacing Doug Ingram, who plans to retire. Severino previously led development roles at AbbVie and Amgen and ran Tessera Therapeutics. The change comes as Sarepta faces Elevidys trial and FDA-related setbacks and declining gene-therapy sales. Sarepta shares were above $158 in June 2024 and trade around $16 now.

Sarepta Therapeutics named Michael Severino CEO, replacing Doug Ingram, who stepped down for personal reasons and will advise until year-end. Ingram cited family DM1 diagnoses. Severino previously led Tessera and held senior roles at AbbVie and Amgen. The article notes prior setbacks, including Elevidys liver-toxicity reports and failed Vyondys 53 and Amondys 45 trials.